As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has made ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...